Author information

¹Department of Digestive and Hepatobiliary Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France.

²Oncology and Medical-Surgical Specialities, Department of Hepatology, AP-HP/Hôpital Cochin, Paris-Cité University/INSERM U1223-U1016, Paris, France.

³Department of Liver Diseases, CHU Rennes, Rennes University/UMR124/INSERM CIC1414, Institut NUMECAN, Rennes, France.

⁴Department of Hepato-Gastroenterology, CHU Limoges, Limoges University/INSERM U1248, Limoges, France.

⁵Department of Hepatology, CHU Toulouse, Toulouse, France.

⁶Department of Hepato-Gastroenterology, AP-HP/Hôpital Beaujon, Paris-Cité University/CRI/INSERM UMR1149, Paris, France.

⁷Department of Hepato-Gastroenterology, AP-HP/Hôpital La Pitié Salpétrière, Sorbonne University/INSERM UMR-S938/CRSA/ICAN, Paris, France.

⁸Department of Hepato-Gastroenterology, Hôpital Saint-Joseph, Aix-Marseille University/INSERM UMR1252 IRD/SESSTIM/ISSPAM, Marseille, France.

⁹Department of Hepato-Gastroenterology, CHU Lille, Lille University/INSERM INFINITE-U1286, Lille, France.

¹⁰Department of Hepatology, CHU Bordeaux, Bordeaux, France.

¹¹Department of Hepato-Gastroenterology, CHU Montpellier, Montpellier University/INSERM U1183, Montpellier, France.

¹²Department of Hepatology, AP-HP/Hôpital Henri Mondor, Créteil, France.

¹³Department of Internal Medicine-Clinical Immunology, CHU Toulouse, Toulouse III University/RESTORE INSERM UMR-1301/CNRS-5070/FLAMES Team, Toulouse, France.

¹⁴Department of Hepatology, HCL/Hopital Croix Rousse, INSERM U1052, Institut EVEREST, Lyon, France.

¹⁵Clermont-Auvergne University/CNRS/Clermont-Auvergne INP/Institut Pascal, Clermont-Ferrand, France.

Abstract

Background: Hepatitis C virus genotype 5 (HCV-GT-5) is found mainly in South Africa. In our area in central France, the prevalence of HCV-GT-5 is 14%.

Methods and results: Here we evaluated sustained virological response at week 12 post-treatment (SVR12) in 147 HCV-GT-5 patients from 14 French university hospitals (2014-2021) treated with direct-acting antivirals (DAA) in real-life. Patients had mainly received sofosbuvir/ledipasvir ± ribavirin, sofosbuvir/velpatasvir, and glecaprevir/pibrentasvir. Overall SVR12 was 98% (144/147). Two patients experienced relapse: one was successfully retreated with the same DAAs (sofosbuvir/ledipasvir) plus ribavirin, and the other refused further DAA treatment. One patient with virological failure (sofosbuvir/velpatasvir) had received a second treatment (sofosbuvir/velpatasvir/voxilaprevir) and progressed to cure.

Conclusions: HCV-GT-5 patients treated with a DAA regimen had a 99% SVR12 in intention-to-treat (including initial therapy and retreatment) and 100% SVR12 per protocol. Sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, and glecaprevir/pibrentasvir show very good efficacy in real-world HCV-GT-5 patients.